Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 20;6(1):e70031. doi: 10.1002/mco2.70031

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Estimates of progression‐free survival. (A) The progression‐free survival distributions among enrolled patients. (B) Progression‐free survival in total population. (C) Progression‐free survival among patients who received pyrotinib plus fulvestrant as first‐line treatment. (D) Progression‐free survival among patients with brain metastases. We calculated p‐values using the unadjusted log‐rank test and hazard ratios using univariate Cox regression analysis. CI, confidence interval; HR, hazard ratio; PFS, progression‐free survival.